We are live on ! Find out more
INKT icon

MiNK Therapeutics
INKT

25 hedge funds and large institutions have $1.76M invested in MiNK Therapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

19% more funds holding

Funds holding: 21 → 25 (+4)

0.17% less ownership

Funds ownership: 0.4% → 0.23% (-0.17%)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

70% less capital invested

Capital invested by funds: $5.96M → $1.76M (-$4.2M)

Holders
25
Holders Change
+4
Holders Change %
+19.05%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
6
Reduced
8
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
+$107K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$31K
3
BlackRock
BlackRock
New York
+$21.7K
4
State Street
State Street
Massachusetts
+$14.6K
5
UBS Group
UBS Group
Switzerland
+$4.3K

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$1.86M
2
Millennium Management
Millennium Management
New York
-$306K
3
GTCM
Gyon Technologies Capital Management
New Jersey
-$189K
4
Morgan Stanley
Morgan Stanley
New York
-$128K
5
Invesco
Invesco
Georgia
-$94K
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
$745K -$43.6K -1,450 -4%
AG
2
Artal Group
Luxembourg
$652K – – –
BCM
3
Bridgeway Capital Management
Texas
$80K +$107K +3,550 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$76K +$31K +1,032 +44%
Renaissance Technologies
5
Renaissance Technologies
New York
$58K -$28.1K -934 -27%
BlackRock
6
BlackRock
New York
$40K +$21.7K +724 +70%
State Street
7
State Street
Massachusetts
$38K +$14.6K +485 +41%
Vanguard Group
8
Vanguard Group
Pennsylvania
$23K -$1.26K -42 -4%
New York State Common Retirement Fund
9
New York State Common Retirement Fund
New York
$18K – – –
UBS Group
10
UBS Group
Switzerland
$12K +$4.3K +143 +36%
Bank of America
11
Bank of America
North Carolina
$5K +$451 +15 +8%
TRCT
12
Tower Research Capital (TRC)
New York
$5K +$1.32K +44 +24%
AIG
13
American International Group
New York
$2K -$120 -4 -4%
California State Teachers Retirement System (CalSTRS)
14
California State Teachers Retirement System (CalSTRS)
California
$2K +$2.13K +71 New
JP Morgan Chase
15
JP Morgan Chase
New York
$2K +$2.82K +94 New
Wells Fargo
16
Wells Fargo
California
$1K -$2.28K -76 -63%
AB
17
Amalgamated Bank
New York
$1K +$901 +30 New
AF
18
Amalgamated Financial
New York
$1K +$901 +30 New
Barclays
19
Barclays
United Kingdom
$1K +$991 +33 New
RI
20
RTW Investments
New York
– -$1.86M -41,667 Closed
Millennium Management
21
Millennium Management
New York
– -$306K -6,851 Closed
Morgan Stanley
22
Morgan Stanley
New York
– -$128K -4,248 -100%
GTCM
23
Gyon Technologies Capital Management
New Jersey
– -$189K -4,245 Closed
Invesco
24
Invesco
Georgia
– -$94K -2,107 Closed
Citigroup
25
Citigroup
New York
– -$2.49K -83 -91%
1
2

INKT Hedge Fund Activity: Q1 2022 in Review

25 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q1 2022, worth a combined $1.76M — down 70% from $5.96M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new INKT positions and 4 closed out — a net gain of 4 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $107K. The largest seller was RTW Investments, exiting entirely with an estimated $1.86M sold.

  • 25 institutional investors held MiNK Therapeutics (INKT) as of Q1 2022, up from 21 in Q4 2021.
  • Funds reported $1.76M of MiNK Therapeutics stock for Q1 2022, down 70% quarter-over-quarter.
  • 8 funds opened new MiNK Therapeutics positions in Q1 2022 and 4 closed out, a net change of +4 holders.
  • The largest MiNK Therapeutics buyer in Q1 2022 was Bridgeway Capital Management, an estimated $107K added.
  • The largest MiNK Therapeutics seller in Q1 2022 was RTW Investments, an estimated $1.86M sold.

Based on aggregated 13F filings for Q1 2022.